Company Overview and News

 
IWCity advance; volume doubles

2018-09-14 theedgemarkets
KUALA LUMPUR (Sept 14): Iskandar Waterfront City Bhd (IWCity) shares rose 13 percent, more than any full-day gain since July 19, as Malaysia's benchmark index advanced.
1589

 
KLCI rises 0.43% as index-linked blue chips lift

2018-08-07 theedgemarkets
KUALA LUMPUR (Aug 7): The FBM KLCI rose 0.43% at the midday break today as index-linked blue chip stocks lifted the local benchmark index.
HLFBF 7062 7052 7060 7036 1082 5681 BATS 4162 5014 6033 4634 1783 5029 PNADF 5347 5016 1589 SGPBY TNABY 2739 MYPRY TNABF PNAGF

 
KLCI remains subdued, tracks regional peers

2018-07-30 theedgemarkets
KUALA LUMPUR (July 30): The FBM KLCI remained subdued at the midday break today, tracking its regional peers.
HLFBF APEXF 7090 8621 7036 BATS 4162 5014 5029 3026 5225 3867 1589 2739 IHHHF PNAGF 1082 5681 6033 5139 PNADF 0900 MYPRY Q0F 3719

 
KLCI rises 0.29%, select blue chips lift

2018-07-24 theedgemarkets
KUALA LUMPUR (July 24): The FBM KLCI gained 0.29% at midday break today, tracking the uptrend at most Asian markets, lifted by select index-linked blue chips.
UPBMF 4065 5681 2089 6033 3204 PNADF 3301 7986 3867 1589 5819 0118 PNAGF 1929

 
KLCI rises 0.24%, tracks regional gains

2018-07-24 theedgemarkets
KUALA LUMPUR (July 24): The FBM KLCI rose 0.24% at mid-morning today, tracking regional gains, lifted by select blue chips.
PNADF 3867 1589 7060 4065 7323 2739 PNAGF 6033 9334

 
IWCity shares fall on profit-taking

2018-07-23 thestar.com.my
KUALA LUMPUR: Iskandar Waterfront City Bhd (IWCity) shares were lower in early trade Monday as investors take profit after the recent gains.
1589

 
KLCI drifts lower, tracks regional losses

2018-07-23 theedgemarkets
KUALA LUMPUR (July 23): The FBM KLCI drifted lower this morning, tracking regional markets, weighed by select blue chips.
KLKBY 2445 4588 5183 1589 7216 PECGF

 
IWCity active, falls 6.17% on saying no fresh bid submitted for Bandar Malaysia projects

2018-07-23 theedgemarkets
KUALA LUMPUR (July 23): Iskandar Waterfront City Bhd (IWCity) fell 6.17% in active trade this morning after the company announced that its parent firm, Iskandar Waterfront Holdings Sdn Bhd (IWH), has not submitted a fresh bid for projects related to the development of Bandar Malaysia, whose gross devlopment value was previously estimated to be RM160 billion.
1589

 
Trading ideas: IWCity, Gamuda, Salcon, Cabnet

2018-07-23 thestar.com.my
KUALA LUMPUR: Iskandar Waterfront City Bhd (IWCity), Gamuda Bhd , Salcon Bhd and Cabnet Holdings Bhd are among the stocks to watch on Monday, according to JF Apex Research.
1589

 
KLCI seen trending lower, immediate support at 1,730

2018-07-22 theedgemarkets
KUALA LUMPUR (July 23): The FBM KLCI is trending lower today, in line with the weaker close at most global markets last Friday, with immediate support at 1,730.
5090 5258 1589 5176 5263

 
No fresh attempt to bid for Bandar Malaysia

2018-07-21 thestar.com.my
KUALA LUMPUR: Iskandar Waterfront City Bhd (IWCity) says its parent company Iskandar Waterfront Holdings Sdn Bhd (IWH) has not made any fresh attempt to bid for the development of Bandar Malaysia.
1589

 
Gamuda, IWCity, BIMB, Salcon, Cabnet, SunCon, Sunway REIT and Media Chinese

2018-07-20 theedgemarkets
KUALA LUMPUR (July 20): Based on corporate announcements and news flow, companies that may be in focus on Monday (July 23) include the following: Gamuda Bhd, Iskandar Waterfront City Bhd, BIMB Holdings Bhd, Salcon Bhd, Cabnet Holdings Bhd, Sunway Construction Group Bhd, Sunway Real Estate Investment Trust and Media Chinese International Ltd. Gamuda Bhd’s 40% associate Syarikat Pengeluar Air Selangor Holdings Sdn Bhd (Splash) has withdrawn its claims against Syarikat Bekalan Air Selangor Sdn Bhd (Syabas) in order to facilitate negotiations on the disposal of Splash with the State government of Selangor.
5090 5258 1589 5176 5263

 
IWCity: IWH hasn’t submitted new Bandar Malaysia bid, unaware of reason for sharp rise in share price

2018-07-20 theedgemarkets
KUALA LUMPUR (July 20): Iskandar Waterfront City Bhd (IWCity) announced that its parent firm, Iskandar Waterfront Holdings Sdn Bhd (IWH), has not submitted a fresh bid for projects related to the development of Bandar Malaysia, which was earlier touted to be worth RM160 billion in gross development value.
1589 BSMAF 1818

 
IWCity says IWH did not submit new bid for Bandar Malaysia

2018-07-20 thestar.com.my
KUALA LUMPUR: Iskandar Waterfront City Bhd (IWCity) says parent company Iskandar Waterfront Holdings Sdn Bhd (IWH) has not made any fresh attempt to bid for the development of Bandar Malaysia.
1589

 
Bursa snaps nine-day winning streak to end lower

2018-07-20 malaymail
KUALA LUMPUR, July 20 — Bursa Malaysia snapped a nine-day winning streak to close easier today on technical correction, amid a recovery in the Chinese market and overnight Wall Street decline, said a dealer.
7172 PBLOF 1589 1295 BSMAF 1818

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...